178 related articles for article (PubMed ID: 20383215)
1. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.
Long-Boyle JR; Green KG; Brunstein CG; Cao Q; Rogosheske J; Weisdorf DJ; Miller JS; Wagner JE; McGlave PB; Jacobson PA
Bone Marrow Transplant; 2011 Jan; 46(1):20-6. PubMed ID: 20383215
[TBL] [Abstract][Full Text] [Related]
2. Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.
McCune JS; Mager DE; Bemer MJ; Sandmaier BM; Storer BE; Heimfeld S
Cancer Chemother Pharmacol; 2015 Jul; 76(1):85-96. PubMed ID: 25983023
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
Ivaturi V; Dvorak CC; Chan D; Liu T; Cowan MJ; Wahlstrom J; Stricherz M; Jennissen C; Orchard PJ; Tolar J; Pai SY; Huang L; Aweeka F; Long-Boyle J
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1701-1713. PubMed ID: 28684371
[TBL] [Abstract][Full Text] [Related]
4. A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients.
Salinger DH; Blough DK; Vicini P; Anasetti C; O'Donnell PV; Sandmaier BM; McCune JS
Clin Cancer Res; 2009 Aug; 15(16):5280-7. PubMed ID: 19671874
[TBL] [Abstract][Full Text] [Related]
5. Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.
Sanghavi K; Wiseman A; Kirstein MN; Cao Q; Brundage R; Jensen K; Rogosheske J; Kurtzweil A; Long-Boyle J; Wagner J; Warlick ED; Brunstein CG; Weisdorf DJ; Jacobson PA
Transl Res; 2016 Sep; 175():103-115.e4. PubMed ID: 27094990
[TBL] [Abstract][Full Text] [Related]
6. Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy.
Takahashi T; Scheibner A; Cao Q; Pearson R; Sanghavi K; Weisdorf DJ; Brunstein CG; Rogosheske J; Bachanova V; Warlick ED; Wiseman A; Jacobson PA
Transplant Cell Ther; 2021 Sep; 27(9):773.e1-773.e8. PubMed ID: 34044184
[TBL] [Abstract][Full Text] [Related]
7. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.
McCune JS; Vicini P; Salinger DH; O'Donnell PV; Sandmaier BM; Anasetti C; Mager DE
Cancer Chemother Pharmacol; 2015 Jan; 75(1):67-75. PubMed ID: 25374408
[TBL] [Abstract][Full Text] [Related]
9. A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.
Bemer MJ; Sorror M; Sandmaier BM; O'Donnell PV; McCune JS
Cancer Chemother Pharmacol; 2013 Sep; 72(3):607-18. PubMed ID: 23907443
[TBL] [Abstract][Full Text] [Related]
10. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
[TBL] [Abstract][Full Text] [Related]
11. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide.
Luznik L; Jalla S; Engstrom LW; Iannone R; Fuchs EJ
Blood; 2001 Dec; 98(12):3456-64. PubMed ID: 11719388
[TBL] [Abstract][Full Text] [Related]
12. A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients.
McCune JS; Woodahl EL; Furlong T; Storer B; Wang J; Heimfeld S; Deeg HJ; O'Donnell PV
Cancer Chemother Pharmacol; 2012 Jan; 69(1):263-72. PubMed ID: 21909959
[TBL] [Abstract][Full Text] [Related]
13. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
Kang HJ; Shin HY; Park JE; Chung NG; Cho B; Kim HK; Kim SY; Lee YH; Lim YT; Yoo KH; Sung KW; Koo HH; Im HJ; Seo JJ; Park SK; Ahn HS;
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1582-8. PubMed ID: 20685256
[TBL] [Abstract][Full Text] [Related]
14. Outcome of Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single-Center Study from Pakistan.
Chaudhry QUN; Iftikhar R; Satti TM; Mahmood SK; Ghafoor T; Shamshad GU; Farhan M; Shahbaz N; Khan MA; Khattak TA; Rehman J; Humayun S; Satti HS; Anwer F; Ahmed P
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2375-2382. PubMed ID: 31394274
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X
Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457
[TBL] [Abstract][Full Text] [Related]
16. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
17. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.
Barker JN; Weisdorf DJ; DeFor TE; Blazar BR; Miller JS; Wagner JE
Blood; 2003 Sep; 102(5):1915-9. PubMed ID: 12738676
[TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
Kim H; Lee JH; Joo YD; Bae SH; Hyun MS; Lee JH; Kim DY; Lee WS; Ryoo HM; Kim MK; Park JH; Lee KH;
Ann Hematol; 2012 Sep; 91(9):1459-69. PubMed ID: 22526363
[TBL] [Abstract][Full Text] [Related]
19. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
[TBL] [Abstract][Full Text] [Related]
20. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.
Niederwieser D; Maris M; Shizuru JA; Petersdorf E; Hegenbart U; Sandmaier BM; Maloney DG; Storer B; Lange T; Chauncey T; Deininger M; Pönisch W; Anasetti C; Woolfrey A; Little MT; Blume KG; McSweeney PA; Storb RF
Blood; 2003 Feb; 101(4):1620-9. PubMed ID: 12393457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
